In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on OncoCyte Corp (OCX), with a price target of $7.75. The company’s shares closed yesterday at $5.08.
According to TipRanks.com, Nakae is ranked 0 out of 5 stars with an average return of -14.8% and a 33.7% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and BioSig Technologies Inc.
Currently, the analyst consensus on OncoCyte Corp is a Moderate Buy with an average price target of $7.75.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.92 and a one-year low of $1.17. Currently, OncoCyte Corp has an average volume of 303.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoCyte Corp. is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company was founded in September 2009 and is headquartered in Alameda, CA.
